J. B. Rose

发表

A retrospective observational population‐based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m2 in Ontario, Canada

S. Tobe, B. Millson, Wally Rapattoni, 2020, Diabetes, obesity & metabolism.

Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line.

I. Coe, J. B. Rose, Z. Naydenova, 2008, American journal of physiology. Heart and circulatory physiology.

Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection.

M. Eguchi, G. Sweeney, D. Choi, 2010, American journal of physiology. Heart and circulatory physiology.

Physiology of nucleoside transporters: back to the future. . . .

I. Coe, J. B. Rose, 2008, Physiology.

Characterization of mammalian equilibrative nucleoside transporters (ENTs) by mass spectrometry.

L. Desouza, K. M. Siu, Maria Chalsev, 2010, Protein expression and purification.

CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.

V. Woo, A. Bell, M. Clement, 2019, Canadian journal of diabetes.

The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity

I. Coe, J. B. Rose, Azza Ramadan, 2013, Purinergic Signalling.

Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers

D. Boyne, W. Cheung, D. O’Sullivan, 2022, Current oncology.

Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge.

J. Klawitter, G. Sweeney, D. Choi, 2011, Life sciences.

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets

S. Ou, L. Bazhenova, J. Curtin, 2022, Molecular oncology.

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice

V. Woo, A. Bell, M. Clement, 2018, Diabetes, obesity & metabolism.

Nucleoside transporter expression profiles in human cardiac tissue show striking individual variability with overall predominance of hENT1.

C. Peniston, I. Coe, Z. Pozeg, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity

I. Coe, J. B. Rose, Azza Ramadan, 2013, Purinergic Signalling.

35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

M. Hochmair, A. Spira, A. Panaccione, 2022, Annals of Oncology.

Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge.

J. Klawitter, G. Sweeney, D. Choi, 2011, Life sciences.